In sub-Saharan Africa, herbalists and spiritual healers are working closely with researchers to help reduce HIV transmission in rural communities.
Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.
A recent analysis conducted by the AIDS Treatment Activists Coalition revealed that, among HIV drug trial participants, data specific to race and sex were dramatically underreported.
While findings from the high-profile AMP studies have excited scientists, they’re only one of a wide range of bNAb avenues currently being pursued.
Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.
David Alain Wohl, M.D., shares his thoughts on broadly neutralizing antibodies for COVID-19—and the extent to which we can hope to see similar developments in HIV.
April 1, 2021: The ethics of teaching U=U; the role of primary care in HIV service acceptance; STI testing rates in transgender women; the potential in anal self-sampling.
David Alain Wohl, M.D., talks through new data regarding long-acting antiretroviral therapy for HIV—and touches on the uncertainties clinicians face in incorporating this new treatment method into their practice.
Researchers recommend PrEP programs be linked to a gender-affirming care clinic, to build trust and retain patients in care.
CROI 2021 featured new research on a host of long-acting antiretrovirals in development, including less-frequent treatment injections, a weekly pill for HIV treatment, injectable PrEP, vaginal PrEP rings, and PrEP implants.